Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a Healthcare company (Biotechnology) with a market capitalization of $5.9B. The Maz Rating grades it against the other companies in its sector.
Ligand Pharmaceuticals Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $293.81, Ligand Pharmaceuticals Incorporated trades at 112.7x trailing earnings, 23.0x sales and 6.1x book value, with an EV/EBITDA of 86.5. Over the last twelve months it generated about $255M of revenue and $52M of net income. It runs an operating margin of 11.9% and a net margin of 20.3%. It shows return on equity of 5.2%, return on invested capital of 1.3% and a free cash flow yield of 1.5%. On the balance sheet: a debt-to-equity ratio of 1.20 and a current ratio of 1.22. Over the past 52 weeks the share price ranged from $175.89 to $326.63, with a beta of 1.03.
Ligand Pharmaceuticals Incorporated does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 13 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.